Combination immunotherapy for high-risk resected and metastatic melanoma patients

Ochsner Journal

Volumn 14, Issue 2, 2014, Pages 164-174

  Riker, Adam I ^a   Rossi, Gabriela R ^b   Masih, Prerna ^b   Alsfeld, L C ^c   Denham, Fiona ^d   Tennant, Lucinda ^b   Ramsey, W Jay ^b   Vahanian, Nicholas N ^b   Link, Charles J ^b  

^a ADVOCATE CHRIST MEDICAL CENTER   (United States)

^b NEWLINK GENETICS   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d CARILION CLINIC   (United States)

Author keywords

Alpha galactosyl epitope; Immunotherapy; Melanoma; Peginterferon alfa 2b; Vitiligo

Indexed keywords

MELANOMA VACCINE; NLG 12036; PEGINTERFERON ALPHA2B; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ANTIBODY RESPONSE; APPETITE DISORDER; ARTICLE; BACKACHE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COLD SWEAT; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEMALE; FETUS; FEVER; FIBROSIS; HEADACHE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOTHYROIDISM; IMMUNE RESPONSE; INSOMNIA; LIMB PAIN; LYMPHEDEMA; MALE; METASTATIC MELANOMA; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRURITUS; RIGOR; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN BRUISING; SKIN INDURATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR REGRESSION; VITILIGO; VOMITING;

EID: 84902074623     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem. 1988 Nov 25;263(33):17755-17762.
2. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun. 1988 Jul;56(7):1730-1737.
3. Baumann BC, Forte P, Hawley RJ, Rieben R, Schneider MK, Seebach JD. Lack of galactose-alpha-1,3-galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. J Immunol. 2004 May 15;172(10):6460-6467.
4. Schaapherder AF, Daha MR, te Bulte MT, van der Woude FJ, Gooszen HG. Antibody-dependent cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera. Transplantation. 1994 May 15;57(9):1376-1382.
5. Watier H, Guillaumin JM, Vallée I, et al. Human NK cell-mediated direct and IgG-dependent cytotoxicity against xenogeneic porcine endothelial cells. Transpl Immunol. 1996 Dec;4(4):293-299.
6. Rossi GR, Mautino MR, Unfer RC, Seregina TM, Vahanian N, Link CJ. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha (1,3)-galactosyl epitopes. Cancer Res. 2005 Nov 15;65(22):10555-10561.
7. Rossi GR, Unfer RC, Seregina T, Link CJ. Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopes. Cancer Immunol Immunother. 2005 Oct;54(10): 999-1009. Epub 2005 May 12.
8. Rossi GR, Mautino MR, Awwad DZ, et al. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity. J Immunother. 2008 Jul-Aug; 31(6): 545-554.
9. Link CJ Jr, Seregina T, Atchison R, Hall A, Muldoon R, Levy JP. Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy. Anticancer Res. 1998 Jul-Aug;18(4A):2301-2308.
10. Galili U, LaTemple DC. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today. 1997 Jun;18(6):281-285.
11. Posekany KJ, Pittman HK, Swanson MS, Haisch CE, Verbanac KM. Suppression of Lewis lung tumor development in alpha 1,3 galactosyltransferase knock-out mice. Anticancer Res. 2004 Mar-Apr;24(2B):605-612.
12. Galili U. Autologous tumor vaccines processed to express alphagal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol Immunother. 2004 Nov;53(11):935-945. Epub 2004 Jun 16.
13. Morris JC, Rossi GR, Janik JE, et al. Phase I/II study of antitumor vaccination using lung cancer cells expressing murine a(1,3)galactosyltransferase (aGT) in non-small cell lung cancer (NSCLC) [AACR Annual Meeting abstract 2423]. Cancer Res. 2010 April 15;70(8)Suppl 1.
14. Hardacre JM, Mulcahy MF, Talamoni M, et al. Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: Preliminary analysis of phase II data [Abstract 4059]. J Clin Oncol. 2010; 28:15 Suppl.
15. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7-17.
16. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun; 18(12):2444-2458.
17. Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002 Sep 1;20(17):3703-3718.
18. Brandberg Y, Aamdal S, Bastholt L, et al. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. Eur J Cancer. 2012 Sep;48(13):2012-2019. Epub 2011 Dec 22.
19. Giannelli G, Antonelli G, Fera G, et al. Biological and clinical significance of neutralizing and binding antibodies to interferonalpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol. 1994 Jul;97(1):4-9.
20. Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res. 2001 Dec;21(12):1103-1115.
21. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferonalpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000 Nov;68(5):556-567.
22. Bouwhuis MG, Suciu S, Testori A, et al. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies-EORTC 18991. J Clin Oncol. 2010 May 10;28(14):2460-2466. Epub 2010 Apr 12.
23. Eggermont AM, Suciu S, Santinami M, et al; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12; 372(9633):117-126.
24. Dummer R, Garbe C, Thompson JA, et al. Randomized doseescalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol. 2006 Mar 1;24(7): 1188-1194.
25. Hwu WJ, Panageas KS, Menell JH, et al. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 2006 Jun 1;106(11):2445-2451.
26. Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer. 2002 Jul 15;95(2):389-396.
27. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol. 2002 Sep 15;20(18):3841-3849.
28. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989 Oct;7(9):980-982, 984-986, 989-990.
29. Young WB, Link CJ Jr. Chimeric retroviral helper virus and picornavirus IRES sequence to eliminate DNA methylation for improved retroviral packaging cells. J Virol. 2000 Jun;74(11): 5242-5249.
30. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011 Jun 2;364(22):2119-2127.
31. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-723. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.
32. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-2526. Epub 2011 Jun 5.
33. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010 Aug 26;363(9):809-819.
34. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010 Sep 30;467(7315):596-599.
35. Boasberg PD, Hoon DS, Piro LD, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol. 2006 Dec;126(12): 2658-2663. Epub 2006 Aug 31.
36. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003 Apr;16(2):90-100.
37. Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011 Sep;2(9): 684-694.
38. Byrne KT, Côté AL, Zhang P, et al. Autoimmune melanocyte destruction is required for robust CD8{thorn}memory T cell responses to mouse melanoma. J Clin Invest. 2011 May;121(5): 1797-1809. Epub 2011 Apr 11.
39. Palermo B, Garbelli S, Mantovani S, Giachino C. Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy. J Autoimmune Dis. 2005 Aug 31;2:7.
40. Garbelli S, Mantovani S, Palermo B, Giachino C. Melanocytespecific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? Pigment Cell Res. 2005 Aug;18(4):234-242.
41. Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol. 2010 Feb; 21(2):409-414. Epub 2009 Jul 21.
42. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16;354(7):709-718.